Table 1.

Cohort Information

Subject ID	Age	Sex	Diagnosis	Anti-β2GPI	Anti-domain I β2GPI	Arterial Events	Venous Events	Pregnancy comorbidities	R. int	Anti-R. int DNMT IgG
APS01	27	F	APS + SLE	positive	positive	No	no	HELLP, miscarriages	+	+++
APS02	41	F	APS + SLE	positive	negative	CVA	no	no	+	+
APS03	61	M	APS	positive	positive	CVA	no	no	−	+
APS04	56	F	APS	positive	positive	CVA	no	no	+	+
APS05	49	F	APS	positive	positive	TIA, CVA	PE × 2, DVT × 2	no	++	+
APS06	66	F	APS	positive	negative	stroke	cortical vein thrombosis	no	+	+
APS07	38	F	triple-positive	positive	positive	NA	NA	no	+	+
APS08	47	F	triple-positive	positive	negative	NA	NA	no	+	+
APS09	55	F	APS	positive	positive	TIAs	no	placental blood clots	+	+
APS10	47	M	APS	positive	positive	No	DVT and PE	no	−	++
APS11	70	F	single-positive	positive	negative	NA	NA	no	+	+
APS12	60	M	APS	positive	positive	No	DVT and PE	no	−	+
APS13	45	M	APS	positive	positive	No	DVT	no	+++	++
APS14	50	F	triple-positive + SLE	positive	negative	NA	NA	no	+	+
APS15	40	M	APS	positive	negative	stroke	DVT and PE	no	+	++
NHD01	42	F	healthy	negative	negative	no	no	no	+++	+
NHD02	50	F	healthy	negative	negative	no	no	no	−	+
NHD03	49	F	healthy	negative	negative	no	no	no	+	−
NHD04	23	M	healthy	negative	negative	no	no	no	+	−
NHD05	40	M	healthy	negative	negative	no	no	no	+	−
NHD06	29	M	healthy	negative	negative	no	no	no	+	−
NHD07	23	F	healthy	negative	negative	no	no	no	−	+
NHD08	32	F	healthy	negative	negative	no	no	no	+	++
NHD09	60	F	healthy	negative	negative	no	no	no	+	+
NHD10	48	F	healthy	negative	negative	no	no	no	+	−
NHD11	42	M	healthy	negative	negative	no	no	no	+	+
NHD12	45	F	healthy	negative	negative	no	no	no	+	+
NHD13	21	F	healthy	negative	negative	no	no	no	+	+
NHD14	50	F	healthy	negative	negative	no	no	no	+	+
NHD15	31	F	healthy	negative	negative	no	no	no	+	+
NHD16	55	F	healthy	negative	negative	no	no	no	+	+
NHD17	29	F	healthy	negative	negative	no	no	no	+	+
NHD18	29	F	healthy	negative	negative	no	no	no	+	+
NHD19	47	F	healthy	negative	negative	no	no	no	++	++
NHD20	55	F	healthy	negative	negative	no	no	no	++	+

Study cohort information. APS, antiphospholipid syndrome or at risk (single- or triple-positive, i.e., anti-β₂GPI, aCL, LA; see Table S1); SLE, systemic lupus erythematosus; NHD, normal healthy donor; anti-β₂GPI, anti-β₂GPI IgG autoantibodies (negative < 40.0 chemiluminescent units (CU), positive > 40.0 CU); anti-domain I β₂GPI, anti-β₂GPI domain I-specific IgG autoantibodies (negative < 20 CU, positive > 20 CU); R. int, R. int qPCR relative levels; anti-R. int DNMT IgG, anti-R. int DNA methyltransferase IgG; values were determined to be + when between −1 and 1 SD from the mean, ++ > 1 SD, +++ > 2 SD, − < −1 SD; HELLP, hemolysis elevated liver enzymes low platelets; CVA, cerebrovascular accident; TIA, transient ischemic attack; DVT, deep vein thrombosis; PE, pulmonary embolism; NA, not assessed.